Drugs / durvalumab-680LT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07196384 | Dec 2025 → Oct 2026 expected | esophageal cancer | University Medical Center Groningen | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05450484 | Apr 2023 → Nov 2024 | esophageal cancer | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07653438 | Sep 2026 → Mar 2028 expected | non-small cell lung carcinoma | University Medical Center Groningen | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | durvalumab-680LT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07653438 ↗ |
| Modality | Diagnostic / imaging agent | “The PD-L1-targeted fluorescent tracer durvalumab-680LT” NCT05450484 ↗ |
| Route | Intravenous | “will be administered intravenously” NCT05450484 ↗ |